Weight-loss drug developer BioAge raises $198 million in U.S. IPO
BioAge Labs has raised $198 million after pricing its upsized U.S. initial public offering at the midpoint of the range at $18 per share, the weight-loss drug developer said on Wednesday. The surging popularity of weight-loss drugs,
After BioAge Labs raised nearly $200 million in its IPO this week, several companies are beginning to eye the public markets, ...
California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a ...
BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...
The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...
Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.
BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the ...
The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of popular weight loss medicines like Eli Lilly’s Zepbound.
BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong demand from ...
BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of ...
BioAge Labs (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, visits the Nasdaq ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback